The spin-off, Delphinus Medical Technologies, will market the Detroit institute's tomographic ultrasound and risk assessment system as SoftVue.
Delphinus has already secured SoftVue purchase commitments from several health institutions in the U.S. and abroad, the Karmanos Cancer Institute said. The process to secure U.S. Food and Drug Administration clearance is also underway.
The company plans to use dealer sales organizations in the U.S. for product distribution, as well as build OEM relationships outside of the U.S. Delphinus will be led by CEO William Greenway, chief medical officer Dr. Peter Littrup, and chief technical officer Neb Duric, Ph.D.
Delphinus said it's seeking to raise $5.5 million in venture capital to finance its projected activities for the next 24-30 months.
Copyright © 2009 AuntMinnie.com